» Articles » PMID: 35897831

Promising Biomarkers in Head and Neck Cancer: The Most Clinically Important MiRNAs

Overview
Journal Int J Mol Sci
Publisher MDPI
Date 2022 Jul 28
PMID 35897831
Authors
Affiliations
Soon will be listed here.
Abstract

Head and neck cancers (HNCs) comprise a heterogeneous group of tumors that extend from the oral cavity to the upper gastrointestinal tract. The principal etiologic factors for oral tumors include tobacco smoking and alcohol consumption, while human papillomavirus (HPV) infections have been accused of a high incidence of pharyngeal tumors. Accordingly, HPV detection has been extensively used to categorize carcinomas of the head and neck. The diverse nature of HNC highlights the necessity for novel, sensitive, and precise biomarkers for the prompt diagnosis of the disease, its successful monitoring, and the timely prognosis of patient clinical outcomes. In this context, the identification of certain microRNAs (miRNAs) and/or the detection of alterations in their expression patterns, in a variety of somatic fluids and tissues, could serve as valuable biomarkers for precision oncology. In the present review, we summarize some of the most frequently studied miRNAs (including miR-21, -375, -99, -34a, -200, -31, -125a/b, -196a/b, -9, -181a, -155, -146a, -23a, -16, -29, and let-7), their role as biomarkers, and their implication in HNC pathogenesis. Moreover, we designate the potential of given miRNAs and miRNA signatures as novel diagnostic and prognostic tools for successful patient stratification. Finally, we discuss the currently ongoing clinical trials that aim to identify the diagnostic, prognostic, or therapeutic utility of miRNAs in HNC.

Citing Articles

Extracellular Vesicle microRNAs as Possible Liquid Biopsy Markers in HNSCC-A Longitudinal, Monocentric Study.

Apeltrath C, Simon F, Riders A, Rudack C, Oberste M Cancers (Basel). 2024; 16(22).

PMID: 39594750 PMC: 11593292. DOI: 10.3390/cancers16223793.


A new perspective on diagnostic strategies concerning the potential of saliva-based miRNA signatures in oral cancer.

Prasad M, Sekar R, Priya M, Varma S, Karobari M Diagn Pathol. 2024; 19(1):147.

PMID: 39548527 PMC: 11568613. DOI: 10.1186/s13000-024-01575-1.


Progress in Precision Medicine for Head and Neck Cancer.

Vakili S, Behrooz A, Whichelo R, Fernandes A, Emwas A, Jaremko M Cancers (Basel). 2024; 16(21).

PMID: 39518152 PMC: 11544984. DOI: 10.3390/cancers16213716.


Epithelial‑derived head and neck squamous tumourigenesis (Review).

Shirima C, Bleotu C, Spandidos D, El-Naggar A, Gradisteanu Pircalabioru G, Michalopoulos I Oncol Rep. 2024; 52(4).

PMID: 39219259 PMC: 11358675. DOI: 10.3892/or.2024.8800.


Head and neck cancer: pathogenesis and targeted therapy.

Liu Y, Zhang N, Wen Y, Wen J MedComm (2020). 2024; 5(9):e702.

PMID: 39170944 PMC: 11338281. DOI: 10.1002/mco2.702.


References
1.
Yang C, Hung P, Wang P, Liu C, Chu T, Cheng H . miR-181 as a putative biomarker for lymph-node metastasis of oral squamous cell carcinoma. J Oral Pathol Med. 2011; 40(5):397-404. DOI: 10.1111/j.1600-0714.2010.01003.x. View

2.
Zhiping C, Shijun T, Linhui W, Yapei W, Lianxi Q, Qiang D . MiR-181a promotes epithelial to mesenchymal transition of prostate cancer cells by targeting TGIF2. Eur Rev Med Pharmacol Sci. 2017; 21(21):4835-4843. View

3.
Shi H, Chen J, Li Y, Li G, Zhong R, Du D . Identification of a six microRNA signature as a novel potential prognostic biomarker in patients with head and neck squamous cell carcinoma. Oncotarget. 2016; 7(16):21579-90. PMC: 5008307. DOI: 10.18632/oncotarget.7781. View

4.
Ye J, Li L, Feng P, Wan J, Li J . Downregulation of miR-34a contributes to the proliferation and migration of laryngeal carcinoma cells by targeting cyclin D1. Oncol Rep. 2016; 36(1):390-8. DOI: 10.3892/or.2016.4823. View

5.
Wang B, Zhang S, Tong F, Wang Y, Wei L . HPV HNSCC-derived exosomal miR-9-5p inhibits TGF-β signaling-mediated fibroblast phenotypic transformation through NOX4. Cancer Sci. 2022; 113(4):1475-1487. PMC: 8990726. DOI: 10.1111/cas.15281. View